Toward comprehensive value assessment for Alzheimer's disease innovations.
| Autor: | Ferrell PB; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA., Fillit H; Alzheimer's Drug Discovery Foundation and Icahn School of Medicine at Mount Sinai, New York, New York, USA., Neumann PJ; Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, Massachusetts, USA., Wall JK; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA., Murray JF; Davos Alzheimer's Collaborative, Wayne, Pennsylvania, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Alzheimer's & dementia : the journal of the Alzheimer's Association [Alzheimers Dement] 2023 Apr; Vol. 19 (4), pp. 1558-1567. Date of Electronic Publication: 2022 Nov 25. |
| DOI: | 10.1002/alz.12874 |
| Abstrakt: | Introduction: Assessing medical technologies for Alzheimer's disease (AD) creates challenges for current methods of value assessment. New value assessment approaches for AD are also needed. Methods: We adapted concepts from health economics to help guide decision makers to more informed decisions about AD therapies and diagnostics. Results: We propose a value framework based on five categories: perspective, value elements, analysis, reporting, and decision making. AD value assessments should include the perspective of the patient-caregiver dyad. We propose a broader array of value elements than currently used. Analytics and decision methods can synthesize evidence for all elements of value. Decisions should use a "deliberative appraisal" approach informed by the composite evidence and be transparently reported. Discussion: Using the proposed framework, the value of forthcoming innovations for AD may be more thoroughly assessed for and by all stakeholders. It can guide decision makers to carefully consider all relevant elements of value contributing to more holistic and transparent decision making. Research Highlights: Alzheimer's disease challenges common methods of evaluating medical technology. Using current methods, new AD innovations might not be appropriately valued. Poor value assessments will adversely affect patient access to AD innovations. A full AD value framework expands perspective, elements, analysis, decision-making, reporting. (© 2022 Eli Lilly and Company and The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|